Pharmacokinetic/pharmacodynamic modeling of methylprednisolone effects on iNOS mRNA expression and nitric oxide during lpsinduced inflammation in rats

Pharmaceutical Research

Volumn 29, Issue 8, 2012, Pages 2060-2069

  Sukumaran, Siddharth ^a   Lepist, Eve Irene ^a   DuBois, Debra C ^a   Almon, Richard R ^a,b   Jusko, William J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Bioinformatics and Life Sciences   (United States)

Author keywords

Corticosteroids; Inflammation; INOS; Nitric oxide; PK PD modeling

Indexed keywords

CORTICOSTERONE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHYLPREDNISOLONE SODIUM SUCCINATE; NITRIC OXIDE; SODIUM NITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION; GENETIC TRANSCRIPTION; INFLAMMATION; LOW DRUG DOSE; LUNG PARENCHYMA; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; GENE EXPRESSION REGULATION; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; METHYLPREDNISOLONE; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED LEW; RNA, MESSENGER;

EID: 84864433717     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0733-5     Document Type: Article

References (35)

1. Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med. 2000;6:347-73.
2. Shahand NS, Billiar TR. Role of nitric oxide in inflammation and tissue injury during endotoxemia and hemorrhagic shock. Environ Health Perspect. 1998;106 Suppl 5:1139-43.
3. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424.
4. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem. 2003;384:1343-64.
5. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603-13.
6. Di RosaM, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun. 1990;172:1246-52.
7. Khanduja KL, Kaushik G, Khanduja S, Pathak CM, Laldinpuii J, Behera D. Corticosteroids affect nitric oxide generation, total free radicals production, and nitric oxide synthase activity in monocytes of asthmatic patients. Mol Cell Biochem. 2011;346:31-7.
8. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. Mol Pharmacol. 1996;49:15-21.
9. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol. 1997;273:G1290-6.
10. Jeon YJ, Han SH, Lee YW, Yea SS, Yang KH. Inhibition of NFkappa B/Rel nuclear translocation by dexamethasone: mechanism for the inhibition of iNOS gene expression. Biochem Mol Biol Int. 1998;45:435-41.
11. Linehan JD, Kolios G, Valatas V, Robertson DA, Westwick J. Effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action? Am J Physiol Gastrointest Liver Physiol. 2005;288:G261-7.
12. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol. 2004;96:831-9.
13. Veszelovsky E, Holford NH, Thomsen LL, Knowles RG, Baguley BC. Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. Cancer Chemother Pharmacol. 1995;36:155-9.
14. Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ. Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. J Pharm Sci. 2005;94:590-603.
15. Haughey DB, Jusko WJ. Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J Chromatogr. 1988;430:241-8.
16. DuBois DC, Almon RR, Jusko WJ. Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal Biochem. 1993;210:140-4.
17. Samtani MN, Pyszczynski NA, Dubois DC, Almon RR, Jusko WJ. Modeling glucocorticoid-mediated fetal lung maturation: II. Temporal patterns of gene expression in fetal rat lung. J Pharmacol Exp Ther. 2006;317:127-38.
18. D'Argenio D, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
19. Lazaron V, Dunn DL. Molecular biology of endotoxin antagonism. World J Surg. 2002;26:790-8.
20. Mishina EV, Jusko WJ. Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. Pharm Res. 1996;13:141-5.
21. Garg V, Hon YY, Jusko WJ. Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. Pharm Res. 1994;11:541-4.
22. Sanders SP. Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic? Am J Respir Cell Mol Biol. 1999;21:147-9.
23. van der Vliet A, Eiserich JP, Cross CE. Nitric oxide: a proinflammatory mediator in lung disease? Respir Res. 2000;1:67-72.
24. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:179-89.
25. Sioutas A, Ehren I, Lundberg JO, Wiklund NP, Gemzell- Danielsson K. Intrauterine nitric oxide in pelvic inflammatory disease. Fertil Steril. 2008;89:948-52.
26. Menaka KB, Ramesh A, Thomas B, Kumari NS. Estimation of nitric oxide as an inflammatory marker in periodontitis. J Indian Soc Periodontol. 2009;13:75-8.
27. Yao Z, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetic/ pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2008;97:2820-32.
28. Beishuizen A, Thijs LG. Endotoxin and the hypothalamopituitary- adrenal (HPA) axis. J Endotoxin Res. 2003;9:3-24.
29. Sukumaran S, Almon RR, DuBois DC, Jusko WJ. Circadian rhythms in gene expression: relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010;62:904-17.
30. Givalois L, Dornand J, Mekaouche M, Solier MD, Bristow AF, Ixart G, et al. Temporal cascade of plasma level surges in ACTH, corticosterone, and cytokines in endotoxin-challenged rats. Am J Physiol. 1994;267:R164-70.
31. Hawes AS, Rock CS, Keogh CV, Lowry SF, Calvano SE. In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect Immun. 1992;60:2641-7.
32. Parrott RF, Vellucci SV, Goode JA, Lloyd DM, Forsling ML. Interrelated adrenocortical and neurohypophysial responses associated with fever in endotoxin-treated pigs. Am J Physiol. 1997;273:R1046-52.
33. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75:639-53.
34. Walker G, Pfeilschifter J, Kunz D. Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in posttranscriptional regulation. J Biol Chem. 1997;272:16679-87.
35. Shinoda J, McLaughlin KE, Bell HS, Swaroop GR, Yamaguchi S, Holmes MC, et al. Molecular mechanisms underlying dexamethasone inhibition of iNOS expression and activity in C6 glioma cells. Glia. 2003;42:68-76.